---
id: mycetoma_345
category: organisms
tags: [mycetoma, eumycetoma, actinomycetoma, Madura-foot, grains, Nocardia, Madurella, fosravuconazole, TMP-SMX]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Mycetoma (Madura Foot)

**Q:** What is the clinical triad of mycetoma, how do you differentiate eumycetoma vs actinomycetoma, and what are the treatments (2024 update on fosravuconazole)?

**A:**

**Overview:**
- Chronic progressive granulomatous infection of skin, subcutaneous tissue, fascia, bone
- Endemic: **"Mycetoma belt"** (tropical/subtropical: Sudan, Mexico, India, Venezuela, Chad, Senegal)
- Transmission: **Traumatic inoculation** (thorns, walking barefoot)
- Most common site: **Foot (70% of cases)** → "Madura foot"

**Classification:**

| Type | Causative Agents | Grain Color | Treatment Response | Prognosis |
|------|-----------------|-------------|-------------------|-----------|
| **Eumycetoma** (fungal) | *Madurella mycetomatis* (most common), *Madurella grisea*, *Scedosporium*, *Acremonium* | **Black or white** (black grains = always fungal) | **Resistant** to medical therapy; requires surgery | Poor; may need amputation |
| **Actinomycetoma** (bacterial) | *Nocardia* species (most common: *N. brasiliensis*), *Actinomadura madurae*, *Streptomyces somaliensis* | **White, yellow, red/pink** (red/pink = always bacterial) | **Responsive** to antibiotics | Good with medical therapy |

**Clinical Triad (Classic Presentation):**

1. **Tumor (painless swelling)**: Firm, woody swelling/mass
2. **Sinuses (draining tracts)**: Multiple fistulae discharge purulent material
3. **Grains**: Visible granules in discharge (microcolonies of causative organism)

**Grain Color Diagnostic Value:**

| Grain Color | Diagnosis |
|-------------|-----------|
| **Black/dark grains** | **Always eumycetoma** (fungal) |
| **Red/pink grains** | **Always actinomycetoma** (bacterial) |
| **White/pale yellow** | **Either eumycetoma OR actinomycetoma** (requires culture/histology to distinguish) |

**Why Differentiation Matters:**
- **Actinomycetoma**: Responds well to **antibiotics alone** (cure possible)
- **Eumycetoma**: Generally **resistant** to antifungals; requires **surgery** (may need amputation)
- Management and prognosis completely different despite identical clinical appearance

**Diagnosis:**
- **Clinical**: Triad + grain color
- **Direct microscopy**: Examine grains (fungal hyphae vs bacterial filaments)
- **Culture**: Gold standard for species identification (slow-growing; may take weeks)
- **Histology**: Biopsy showing grains with surrounding granulomatous inflammation
- **Imaging**: MRI for bone involvement (critical for surgical planning)

**Treatment:**

**Actinomycetoma (Bacterial):**

| Regimen | Drugs | Duration | Notes |
|---------|-------|----------|-------|
| **Welsh regimen** | TMP-SMX + amikacin | 5-week cycles (repeat multiple times) | Traditional approach |
| **Ramam regimen** | **Intensive phase**: TMP-SMX + gentamicin (4 weeks)<br>**Maintenance phase**: TMP-SMX + doxycycline | Continue until cure (months) | More practical for resource-limited settings |
| **Alternative** | Amoxicillin-clavulanate, imipenem, rifampin | Variable | For resistant cases |

**Eumycetoma (Fungal):**

| Agent | Dosing | Duration | Notes |
|-------|--------|----------|-------|
| **Itraconazole** (traditional) | 400 mg PO daily | **6 months → surgery** | Standard of care; expensive in endemic areas |
| **Fosravuconazole** (NEW 2024) | 300 mg PO weekly | Months-years | **Phase II trials 2023-2024**: Safe, effective, **much cheaper** than itraconazole; critical for resource-limited settings |
| **Posaconazole** | 300 mg PO BID × 1 day, then 300 mg daily | Months-years | Alternative; expensive |
| **Voriconazole** | 200-400 mg PO BID | Months-years | For *Fusarium* species |

**Fosravuconazole (2024 Breakthrough):**
- **Phase II trials (2023)**: Safe, patient-friendly, effective for eumycetoma
- **Key advantage**: **Much cheaper** than itraconazole
- **Impact**: Critical for young adults in poorer, rural endemic areas where eumycetoma predominantly occurs
- **Status**: Emerging as first-line alternative to itraconazole

**Surgery:**
- **Actinomycetoma**: Usually not needed if medical therapy started early
- **Eumycetoma**: Often requires **wide local excision** or **amputation** if bone involvement extensive

**Key Points:**
- **Triad**: Tumor (swelling) + sinuses (draining tracts) + grains
- **Black grains**: Always fungal (eumycetoma)
- **Red/pink grains**: Always bacterial (actinomycetoma)
- **Actinomycetoma**: Responds to TMP-SMX + aminoglycoside
- **Eumycetoma**: Requires antifungals (itraconazole or **fosravuconazole [2024]**) + surgery
- **Fosravuconazole**: Cheaper alternative to itraconazole (Phase II trials 2023-2024)

**Mnemonic - "Mycetoma Makes: Tumor, Tracts (sinuses), Three-colored grains (black/white/red)"**

**Pearl:** Mycetoma triad: tumor (swelling), sinuses (draining tracts), grains. Black grains = always fungal (eumycetoma); red/pink = always bacterial (actinomycetoma). Actinomycetoma responds well to TMP-SMX + aminoglycoside. Eumycetoma resistant to antifungals; requires itraconazole × 6 months → surgery (or amputation if bone involved). 2024 breakthrough: fosravuconazole (cheaper, effective alternative to itraconazole; Phase II trials 2023).

**Media:**

**Sources:** [StatPearls Eumycetoma NBK574511], [PMC5527712 - Mycetoma Update], [Medscape Mycetoma Overview], [Johns Hopkins ABX Guide - Mycetoma], [Phase II Fosravuconazole Trial 2023]
